NCT04894825 2023-11-27
Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 1 Unknown
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Yantai Yuhuangding Hospital
Yantai Yuhuangding Hospital
Sun Yat-sen University
Sun Yat-sen University
National Cancer Institute (NCI)